目的 探索注射用益氣復脈（凍干，YQFM）對環(huán)磷酰胺致免疫低下小鼠的影響。方法 ICR小鼠隨機分為5組：對照組，模型組，注射用益氣復脈高、中、低劑量（1417.00、708.50、354.25 mg/kg）組，尾iv給藥，每天1次，連續(xù)6 d，于第2天給藥后，ip環(huán)磷酰胺100 mg/kg制備小鼠免疫低下模型。尾iv印度墨汁檢測小鼠炭廓清功能；檢測小鼠脾臟指數(shù)；ip 5%雞紅細胞懸液檢測血清溶血素水平；采用2，4-二硝基氯苯（DNCB）建立耳廓遲發(fā)型超敏反應(yīng)模型，觀察各組小鼠耳腫脹度的變化；動物血液分析儀測定小鼠白細胞數(shù)和骨髓有核細胞數(shù)變化。結(jié)果 與對照組比較，高、中、低劑量的YQFM均可顯著促進免疫低下小鼠的炭廓清功能，顯著增加脾臟指數(shù)、骨髓有核細胞數(shù)和白細胞數(shù)（P<0.05、0.01、0.001）；高劑量可顯著增加溶血素的生成（P<0.05）；中、低劑量顯著增強遲發(fā)型超敏反應(yīng)（P<0.05、0.01）。結(jié)論 YQFM可顯著改善環(huán)磷酰胺導致的小鼠免疫低下，有望成為一種新的抗腫瘤輔助用藥。

Objective To investigate effect of Yiqi Fumai Injection (freeze drying, YQFM) on immunosuppression induced by cytoxan in mice. Methods ICR mice were divided into five groups:control group, model group, YQFM high, medium, and low dose (1417.00, 708.50, and 354.25 mg/kg) groups, iv relative drug in tail once daily for 6 d. Immunosuppression was induced by ip injection of cytoxan (100 mg/kg) after the second administration of YQFM. Clearance function of mice was detected through iv India ink in tail, and spleen index was detected. Detection of serum hemolysin level was taken by ip injection of 5% red blood cells. Using 2,4-dinitrochlorobenzene (DNCB) to establish the delayed-type hypersensitivity model, the changes of ear swelling degree were observed. Changes in the number of leucocyte and bone marrow nucleated cells in mice were determined by animal blood analyzer. Results Compared with control group, YQFM of high, medium, and low doses could significantly promote the immunosuppressive mice's carbon clearance function, and significantly increased the spleen index and the number of leucocyte and bone marrow nucleated cells (P<0.05, 0.01, and 0.001); high dose YQFM could significantly increase the production of hemolysin (P<0.05); and low dose significantly enhance delayed-type hypersensitivity (P<0.05 and 0.01). Conclusion YQFM can significantly improve the immunosuppression of mice caused by cyclophosphamide, and is expected to become an antineoplastic assistant drug.

天津市科技小巨人領(lǐng)軍企業(yè)培育重大項目（14ZXLJSY00240）